Managing cardiovascular risk in patients with diabetes

British Journal of Diabetes and Vascular Disease

Volumn 5, Issue 6, 2005, Pages 325-329

  Donnelly, Richard ^a  

^a DERBY CITY GENERAL HOSPITAL   (United Kingdom)

Author keywords

ACE inhibitor; Cardiovascular disease; Diabetes; Hypertension; Metabolic syndrome

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PERINDOPRIL; PIOGLITAZONE; PLACEBO; QUINAPRIL; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INTRAOCULAR HEMORRHAGE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIFESTYLE; META ANALYSIS; METABOLIC SYNDROME X; REVIEW; RISK FACTOR; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW;

EID: 30544454093     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514050050060501     Document Type: Review

References (24)

1. Diabetes in the UK 2004: Diabetes UK, 2004: 1-27.
2. Chan JC, Cheung JC, Stehouwer CD et al. The central roles of obesity associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome - an analaysis by structural equation modelling. Int J Obes Realt Metab Disord 2002;26:994-1008.
3. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
4. Alberti KGM, Zimmet, P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. Lancet 2005;366:1059-62.
5. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005.
6. Yki-Järvinen H. The PROactive study: some answer, many questions. Lancet 2005;366:1241-2.
7. Dormandy J, Charbonnel B, Eckland D et al. On behalf of the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial in microVascular Events): a randomized controlled clinical trial. Lancet 2005;366:1279-89.
8. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
9. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992;268:1292-300.
10. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
11. MRC/BHF Heart PRotection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
12. Cholesterol Treatment Trialists' Collaborators, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
13. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.
14. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
15. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828.
16. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
17. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
18. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
19. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
20. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005;26:1369-78.
21. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study BMJ 2000;321:1440-4.
22. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005;45:880-6.
23. Braunwald E, Domanski MJ, Fowler SE et aL Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-68.
24. Pilote L, Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E. Mortality rates in elderly patients who take different angiotensin-conventing enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004;141:102-12.